Health and lifestyle features.
Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the “Company” or “Fobi”), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that the company’s wholly-owned subsidiary, PulseIR, has signed a new deal with integrated healthcare provider, Empower Clinics. Empower offers a telemedicine platform for healthcare and diagnostics solutions across the U.S. […]
Continue Reading
EVQLV Inc. and Libera Bio S.L. have signed a collaboration agreement to jointly address intracellular targets, some of the most elusive cancer targets that represent high unmet medical needs. Antibodies can be designed to address very specific targets along cancer pathways Many of the best-validated intracellular cancer targets have been deemed “undruggable” because large molecules cannot […]
Continue Reading
ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has closed a fully subscribed private placement […]
Continue Reading
On October 12, St. Moritz celebrates its grand opening in Centennial, Colorado. St. Moritz plans to operate 100 massage schools across the country and the first location is in the Denver Metro area. Consumers are starting to see it is getting more and more difficult to get a massage due to the high […]
Continue Reading
ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, announced today that it has appointed Gail M. Farfel, Ph.D., as Chief Executive Officer, effective September 19, 2022. New CEO brings 25 years’ experience […]
Continue Reading
ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, today announced details of its poster presentation at the annual Alzheimer’s Association International Conference (AAIC®) being held from July 31-August 4, 2022 […]
Continue Reading
ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced it will give a poster presentation at the annual Alzheimer’s Association International Conference (AAIC®) to be held July 31-August 4, […]
Continue Reading
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has filed a registration statement on Form 10 (the “Registration Statement”) with the United […]
Continue Reading
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, is pleased to announce that it has entered into debenture amendments with seven (7) creditors to settle an […]
Continue Reading
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has amended its articles to authorize the issuance of 70,000,000 Series 1 Preferred Shares […]
Continue Reading
